Overview:
The management of chronic graft-versus-host disease (GVHD) has been reshaped with the development of novel prophylactic approaches, including post-transplant cyclophosphamide, addition of targeted therapies, and graft engineering. In addition, novel targeted therapies have been introduced along the therapeutic continuum, offering the opportunity to extend benefit through effective treatment sequencing.
In this live, 60-minute symposium, experts in the prevention
and management of GVHD will offer insights into optimal selection of
prophylactic and therapeutic approaches to managing this complication.
Case-based scenarios will serve as the platform for discussion on challenges
that persist with respect to treatment selection and sequencing, as well as how
novel approaches can be incorporated into the clinical setting.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Evaluate emerging GVHD prophylaxis strategies and their potential impact on reducing chronic GVHD burden following allo-HCT
- Interpret key clinical trial data supporting the use approved and emerging agents for chronic graft-versus-host disease (cGVHD)
- Apply current evidence to select the most appropriate treatment option for patients with steroid-refractory cGVHD
- Identify and manage adverse events associated with systemic therapies for cGVHD to optimize tolerability and long-term outcomes
Carrie L. Kitko, MD
Ingram Professorship in Pediatric Oncology
Medical Director, Pediatric Stem Cell Transplant Program
Vanderbilt University Medical Center
Nashville, TN
Amandeep Salhotra, MD
Associate Professor, Division of Leukemia
Department of Hematology & Hematopoietic Cell Transplantation
City of Hope
Duarte, CA
Miguel-Angel Perales, MD
Memorial Sloan Kettering Cancer Center
New York, NY
2026 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR are sponsored by the Medical College of Wisconsin.
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education to physicians.
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians and nurses should claim only the credit commensurate with the extent of their participation in the activity.